The XTEND-CIU study: long term use of Omalizumab in Chronic Idiopathic Urticaria

These data support omalizumab safety and efficacy in patients with antihistamine-resistant CIU/CSU to 48 weeks and provide evidence of omalizumab re-treatment efficacy and safety.

http://ift.tt/2AtPYxZ